Future clinical studies demonstrating the use of anti-IL-8 neutralizing antibodies, AR-siRNA, or MMPs inhibitors to inhibit IL-8/AR/MMPs signaling to partially reverse the ability of B cells to invade BCA for the treatment of BC and to prevent the further development of BC point to new research directions [53]. This evidence concerns the gene CXCL8 and breast cancer.